Mark Garzotto, MD, discusses phase 3 data on aglatimagene besadenovec plus standard-of-care external beam radiation therapy with or without short-course androgen deprivation therapy in localized prostate cancer.
Mark Garzotto, MD
Advertisement
Articles by Mark Garzotto, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
2
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
3
Talazoparib/enzalutamide approved for HRR-mutated mAPMN/S prostate cancer
4
In situ immunotherapy shows encouraging survival findings in prostate cancer
5